NCCN Basal Cell Carcinoma Guidelines

Overview / Definition Basal Cell Carcinoma (BCC) is a malignant neoplasm arising from the basal layer of the epidermis. It is characterized by slow growth, local invasion, and a very low metastatic potential. BCC is the most prevalent skin cancer in the United States, often associated with sun exposure and certain genetic syndromes. Epidemiology Basal Cell Carcinoma accounts for approximately 80% of non-melanoma skin cancers. The incidence of BCC continues to rise, particularly among fair-skinned populations. Risk factors include: Chronic sun exposure History of skin cancer Immunosuppression Genetic predisposition (e.g., Gorlin syndrome) Older age Pathophysiology / Mechanism The pathogenesis of BCC involves dysregulation of the Hedgehog signaling pathway, leading to uncontrolled cell proliferation in the basal cell layer. Genetic mutations, particularly in the PTCH1 gene, play a critical role in tumor development. Environmental factors, notably ultraviolet (UV) radiation, further contribute to the oncogenic process. Clinical Presentation BCC typically presents as: Shiny, pearly nodules with telangiectasia Crusted or ulcerated lesions Flat, scaly patches (sclerosing BCC) Pigmented variants Common sites include the face, neck, ears, and scalp. Symptoms may be minimal, and many patients report a history of slowly growing lesions. Diagnosis / Workup The diagnosis of BCC is primarily clinical, supported by: Dermatoscopy to evaluate surface characteristics Biopsy (shave, punch, or excisional) for histopathological confirmation Assessment of clinical staging using the AJCC system Imaging studies are rarely necessary unless there is concern for aggressive disease or regional metastasis. Treatment / Management Management of BCC is guided by tumor size, location, histological subtype, and patient factors. Treatment options include: Mohs micrographic surgery for high-risk or cosmetically sensitive areas Electrodessication and curettage for superficial BCCs Topical therapies (e